posted
The research is conducted in Israel. I recently sent an E-mail asking if the latest conflict was affecting their research. Uri proptly replied that the conflict in the NORTH was not affecting them. I assume they are far enough south not to worry. I also suggested they send out some PR to reassure the investors. If any PR comes out this LOW FLOAT it will move quick. Chart looks great and the potential revenue from their research is stagggering. http://www.tissera.com/Posts: 18 | From: New Hampshire | Registered: Jul 2006
| IP: Logged |
posted
ready to rock this one...chart on a huge triangle breakout! this has no resistzance at all and MMs imo lack shares...they move fast...back to $1 here we come
Posts: 375 | From: New Jersey | Registered: Apr 2005
| IP: Logged |
posted
*****'s #1 pick for 2007. MM's disappearing quick in pre-market, this will probably go from .20 to .25 very quick. Big move from .11 to .19 last Wednesday through Friday on relatively light volume. No PR's since 2004 and no revenues, but that's biotech. If the pump machine comes out like he says he's going to, could be a quick mover:
I can't stress enough how important it is that TSSR only has 27.8 million shares outstanding with 12 million in the float.
When TSSR ran to $8 in 2004, there were 22.4 million shares outstanding. There are only 5.4 million more shares today.
The best thing is... all of the money TSSR raised was at $1.75. Therefore, I see absolutely no resistance until we head back up there!!!
I expect this to be smooth sailing all the way up, except for daytraders taking profits here and there.
Remember... TSSR is my #1 pick for 2007.
This is a true undiscovered gem. The company has made so many breakthroughs during the past couple of years but it has all gone unnoticed by Wall Street. TSSR has been quiet with the press releases although they have provided updates at: http://www.tissera.com.
TSSR is working to use embryonic stem cells to change the entire process of organ transplants.
There are so many millions of people around the world in need of organ transplants but a shortage of donor tissue forces patients to wait years for a suitable organ.
TSSR's future tissue products will potentially be available on demand, eliminating the need to wait years for organ transplantation.
The other problem with organ transplants is that heavy immune suppression is needed to ascertain engraftment. This causes many long term complications.
TSSR's transplant technology minimizes the need for immunosuppressive drugs.
TSSR has been developing everything at the Weizman Institute of Science. TSSR's technology was recently described in a landmark study published in Nature Medicine magazine.
Do your own research on TSSR immediately! Don't make investment decisions based on what I say. Even though TSSR is my #1 pick for 2007, you could still lose all of your money in this stock.
-----
-------------------- I may be wrong, but I don't think so.... Posts: 837 | From: Madison, WI | Registered: Sep 2005
| IP: Logged |
posted
Doesn't get much better than 100% buy......
TSSR - TISSERA INC (OTCBB)
Date Open High Low Last Change Volume % Change 12/04/06 0.2050 0.2450 0.1940 0.2450 +0.0550 2116000 +28.95%
Composite Indicator Trend Spotter TM Buy
Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Buy 20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy 20-Day Average Volume - 421310
Medium Term Indicators 40 Day Commodity Channel Index Buy 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Buy 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy 50-Day Average Volume - 218344
Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy 100-Day Average Volume - 161680
posted
Its looking like .20 is a good buy in point. I'm itching, but I haven't pulled the trigger yet.
Posts: 1028 | From: Georgia | Registered: Jul 2005
| IP: Logged |
posted
Chart is looking positive. I guess I'll check it out first thing tomorrow and see if this is going to continue upward.
Posts: 1028 | From: Georgia | Registered: Jul 2005
| IP: Logged |
posted
Looks like this one has been trading sideways. Maybe a decent move up today is in order.
Posts: 1028 | From: Georgia | Registered: Jul 2005
| IP: Logged |
posted
Tissera Reports Successful Equity Financing Designed for Completion of Pre-Clinical Studies on Primate Diabetic Models Monday January 8, 9:30 am ET
HERZLIYA, Israel--(BUSINESS WIRE)--Tissera, Inc. (OTCBB:TSSR - News) reports that it has completed an additional equity financing round amounting to a gross of $1,650,000 before related expenses. This sum was raised from existing Tissera institutional investors. ADVERTISEMENT
The current proceeds are earmarked for the continuing support and enhancing of the ongoing preclinical studies being performed on primate models of type I (insulin-dependent) diabetes mellitus, as a preparation for the initiation of human clinical studies on diabetic patients. The research activity of the company is performed at the Weizmann Institute of Science.
Amos Eiran, Tissera's Chairman & CEO adds: "We are extremely pleased with the success of this additional fund raising round, which is a strong expression of the investors' belief in our company. The proceeds raised will be used to support the completion of the preclinical studies on primate diabetic models, designed to demonstrate the curative potential of the company's proprietary transplantation technology. Those studies, if successfully concluded as we hope and expect, will enable us to apply for the authorization to start human clinical studies on type I diabetes patients."
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world's population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
About Tissera
Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed by Professor Yair Reisner and his team at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted in mice embryonic human and porcine organ precursor tissues, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.
For more information please visit Tissera website:
"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Such statements, including statements regarding freedom to operate, patentability, infringement, clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."
Contact: Tissera Inc. Dr. Uri Elmaleh, +972-52-5716669 uri*tissera.com
posted
Is there any one particular thing that you guys are looking for in this thing to make it pop, b/c from the looks of it, it's been pretty steady for quite some time.
-------------------- YOU CAN'T LOSE IF YOU DON'T PLAY, BUT YOU CERTAINLY WON'T WIN!! Posts: 71 | From: Nashville, Tn | Registered: Apr 2007
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
